Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clonidine
Drug ID BADD_D00502
Description Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Indications and Usage Clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications.[L7237,L7240] A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient.[L7243] An extended release tablet of clonidine is indicated for the treatment of ADHD either alone or in combination with other medications.[L7246] Clonidine is also used for the diagnosis of pheochromocytoma,[A180565] treatment of nicotine dependance,[A180568] and opiate withdrawal.[A180571]
Marketing Status approved
ATC Code C02AC01; N02CX02; S01EA04
DrugBank ID DB00575
KEGG ID D00281
MeSH ID D003000
PubChem ID 2803
TTD Drug ID D03SKR
NDC Product Code 51862-454; 0597-0033; 69988-0033; 51862-453; 0378-0872; 0591-3510; 0378-0871; 0378-0873; 0597-0032; 0591-3509; 39822-2010; 69238-1426; 50742-247; 0591-3508; 39822-2000; 68134-603; 71511-503; 0597-0031; 51862-455
UNII MN3L5RMN02
Synonyms Clonidine | Klofenil | Clofenil | Chlophazolin | Clonidine Dihydrochloride | Dihydrochloride, Clonidine | Clonidine Hydrochloride | Hydrochloride, Clonidine | Clonidine Monohydrochloride | Monohydrochloride, Clonidine | Clonidine Monohydrobromide | Monohydrobromide, Clonidine | ST-155 | ST 155 | ST155 | Gemiton | Hemiton | Isoglaucon | Klofelin | Clofelin | Clopheline | M-5041T | M 5041T | M5041T | Catapres | Catapresan | Catapressan | Dixarit
Chemical Information
Molecular Formula C9H9Cl2N3
CAS Registry Number 4205-90-7
SMILES C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sneezing22.12.03.024--
Somnolence19.02.05.003; 17.02.04.0060.000295%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Strangury20.02.02.017--Not Available
Suicide attempt19.12.01.0040.000250%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.0070.000114%Not Available
Tearfulness19.15.02.005--Not Available
Tension19.06.02.005--Not Available
Therapeutic response increased08.06.01.021--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Unresponsive to stimuli17.02.05.0310.000045%Not Available
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary retention20.02.02.011--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Withdrawal hypertension24.08.02.009; 08.06.02.007--Not Available
Withdrawal syndrome19.07.06.023; 08.06.02.0120.000100%Not Available
Mental status changes19.07.01.0010.000395%Not Available
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.0090.000154%Not Available
Application site dryness08.02.01.011; 23.03.03.024; 12.07.01.0110.000154%Not Available
Application site papules23.03.03.022; 12.07.01.025; 08.02.01.025--Not Available
Left ventricular dysfunction02.04.02.0110.000045%
Bradyarrhythmia02.03.02.015--Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene